DDrare: Database of Drug Development for Rare Diseases

171. ウィルソン病
［臨床試験数：50，薬物数：59（DrugBank：17），標的遺伝子数：3，標的パスウェイ数：28］

Searched query = "Wilson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 64CuCl2; ALXN1840; Acetate; Artamin 150 mg; Artamin 250 mg; BIS-CHOLINE TETRATHIOMOLYBDATE; Bis-Choline Tetrathiomolybdate; Bis-choline TETRATHIOMOLYBDATE; Bupropion; Bupropion Hydrochloride; COPPER (64CU) CHLORIDE; Celecoxib; Chloride; Choline; Copper; Cuprior; Cuprior 150 mg film-coated tablets; Cuprior 150mg film-coated tablets; D-penicillamine; D-penicillamine 150mg; D-penicillamine 250 mg; DMPS; DMSA; Galactose; Gold; Metalcaptase® 150 mg gastro-resistant tablet; Metalcaptase® 300 mg gastro-resistant tablet; NPC-02; Nitrogen; None; Once a day Trientine; PEMINE - 150 MG CAPSULE RIGIDE 50 CAPSULE; PENICILLAMINE; Penicillamine; Procedure: Fibroscan; Procedure: Functional hepatic nitrogen clearance; Procedure: Liver biopsy; Procedure: Ultrasound; SoC Therapy; Standard of Care Medications; TETA; TETA 4HCL; TETA 4HCl; TETA.4HCI; TETA.4HCl; TRIENTINE DIHYDROCHLORIDE; Tetrathiomolybdate; Trientine; Trientine dihydrochloride; Trientine dihydrochloride 300mg capsules; Trientine tetrahydrochloride; WTX101; Wilzin; ZINC ACETATE DIHYDRATE; ZINC GLUCONATE; Zinc; Zinc acetate; Zinc gluconate; Zink Natur-Drogeriet

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00212355 (ClinicalTrials.gov)	March 2005	13/9/2005	Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan.	Phase3, Open-Label, Clinical Trial of Zinc Acetate for Treatment of Wilson's Disease in Japan.	Wilson's Disease	Drug: NPC-02	Nobelpharma	NULL	Completed	1 Year	N/A	All	37	Phase 3	NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00212355
(ClinicalTrials.gov)

March 2005

13/9/2005

Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan.

Phase3, Open-Label, Clinical Trial of Zinc Acetate for Treatment of Wilson's Disease in Japan.

Wilson's Disease

Drug: NPC-02

Nobelpharma

NULL

Completed

1 Year

N/A

All

Phase 3

NULL